ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2013

Dec 2, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2013-11-22

Reporting Person: Wyrick Susan D. (PAO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-11-22	Stock Option (right to buy)	$7.94	A	7500	Acquired	2023-11-22	Common Stock (7500)	Direct
2013-11-22	Restricted Stock Unit	$	A	3750	Acquired	2017-12-22	Common Stock (3750)	Direct

Footnotes

F1: The options vest in monthly installments over 48 months commencing one month from November 22, 2013.

F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.

F3: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of November 22, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.